Vaccination with virosomally formulated recombinant CyRPA elicits protective antibodies against Plasmodium falciparum parasites in preclinical in vitro and in vivo models
Tags:
Reference:
NPJ Vaccines. 2020; 5:9
The Plasmodium falciparum (Pf) cysteine-rich protective antigen (PfCyRPA) has emerged as a promising blood-stage candidate antigen for inclusion into a broadly cross-reactive malaria vaccine. This highly conserved protein among various geographical strains plays a key role in the red blood cell invasion process by P. falciparum merozoites, and antibodies against PfCyRPA can efficiently prevent the entry of the malaria parasites into red blood cells.
Objectors to applications in public health assert that because it is impossible to obtain informed consent that the technology is inadequate. What a remarkable conclusion!
In the early 1990s, when scientists first came up with a radical new idea to engineer mosquitoes that would no longer be capable of transmitting pathogens, some thought of an even more fantastic application. Use mosquitoes to vaccinate people. Silence followed until now...